Compare · RPID vs WAT
RPID vs WAT
Side-by-side comparison of Rapid Micro Biosystems Inc. (RPID) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RPID and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $40.72B, about 489.0x RPID ($83.3M).
- WAT has been more active in the news (6 items in the past 4 weeks vs 4 for RPID).
- WAT has more recent analyst coverage (25 ratings vs 10 for RPID).
- Company
- Rapid Micro Biosystems Inc.
- Waters Corporation
- Price
- $1.64+1.23%
- $414.21+0.88%
- Market cap
- $83.3M
- $40.72B
- 1M return
- -18.41%
- -
- 1Y return
- -38.23%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 1995
- News (4w)
- 4
- 6
- Recent ratings
- 10
- 25
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest RPID
- SEC Form 10-Q filed by Rapid Micro Biosystems Inc.
- Rapid Micro Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results
- Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Kollender Richard S exercised 3,508 shares at a strike of $0.75, increasing direct ownership by 3% to 133,826 units (SEC Form 4)
- PRESIDENT AND CEO Spignesi Robert G. Jr. exercised 1,402 shares at a strike of $0.75, increasing direct ownership by 0.12% to 1,191,973 units (SEC Form 4)
- Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026
- Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Director Lowenstein Inese was granted 12,787 shares, increasing direct ownership by 22% to 70,687 units (SEC Form 4)
- Director Pei Melinda Litherland was granted 12,787 shares, increasing direct ownership by 15% to 100,687 units (SEC Form 4)
Latest WAT
- SEC Form 8-K filed by Waters Corporation
- SEC Form 10-Q filed by Waters Corporation
- Director Kuebler Christopher A sold $1,442,930 worth of shares (3,626 units at $397.94) and exercised 3,626 shares at a strike of $136.43 (SEC Form 4)
- Waters upgraded by TD Cowen with a new price target
- Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition
- Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
- Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
- RBC Capital Mkts initiated coverage on Waters with a new price target
- Director Knight Heather was granted 63 shares, increasing direct ownership by 5% to 1,281 units (SEC Form 4)
- Director Jiang Wei was granted 67 shares, increasing direct ownership by 2% to 3,573 units (SEC Form 4)